Scilex Holding (NASDAQ:SCLX – Get Free Report) insider Jaisim Shah acquired 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was bought at an average cost of $0.99 per share, with a total value of $29,700.00. Following the completion of the transaction, the insider now directly owns 77,333 shares in the company, valued at $76,559.67. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Scilex Stock Up 9.8 %
SCLX stock traded up $0.08 during mid-day trading on Thursday, hitting $0.95. 1,165,308 shares of the company were exchanged, compared to its average volume of 1,058,459. The firm has a market capitalization of $183.14 million, a P/E ratio of -0.66 and a beta of 1.15. Scilex Holding has a 12-month low of $0.73 and a 12-month high of $2.63. The business has a fifty day simple moving average of $1.04 and a 200-day simple moving average of $1.26.
Scilex (NASDAQ:SCLX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The company had revenue of $16.37 million during the quarter, compared to analyst estimates of $13.17 million. Research analysts predict that Scilex Holding will post -1.19 EPS for the current year.
Hedge Funds Weigh In On Scilex
Analyst Upgrades and Downgrades
Separately, Alliance Global Partners assumed coverage on Scilex in a research note on Wednesday. They set a “buy” rating and a $14.00 price objective for the company.
Get Our Latest Stock Analysis on Scilex
About Scilex
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Featured Articles
- Five stocks we like better than Scilex
- Best Stocks Under $5.00
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Insider Trading – What You Need to Know
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.